Page 30 - Read Online

Mansinho et al. J Cancer Metastasis Treat 2021;7:44 https://dx.doi.org/10.20517/2394-4722.2021.88 Page 11 of 12

28. Paiva R, Gomes I, Casimiro S, Fernandes I, Costa L. c-Met expression in renal cell carcinoma with bone metastases. J Bone Oncol
2020;25:100315. DOI PubMed PMC
29. Hass R, Jennek S, Yang Y, Friedrich K. c-Met expression and activity in urogenital cancers - novel aspects of signal transduction and
medical implications. Cell Commun Signal 2017;15:10. DOI PubMed PMC
30. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol 2003;4:915-
25. DOI PubMed
31. Gibney GT, Aziz SA, Camp RL, et al. c-Met is a prognostic marker and potential therapeutic target in clear cell renal cell carcinoma.
Ann Oncol 2013;24:343-9. DOI PubMed PMC
32. Mukai S, Yorita K, Kawagoe Y, et al. Matriptase and MET are prominently expressed at the site of bone metastasis in renal cell
carcinoma: immunohistochemical analysis. Hum Cell 2015;28:44-50. DOI PubMed PMC
33. Aisen AM, Martel W, Braunstein EM, McMillin KI, Phillips WA, Kling TF. MRI and CT evaluation of primary bone and soft-tissue
tumors. AJR Am J Roentgenol 1986;146:749-56. DOI PubMed
34. O'Sullivan GJ, Carty FL, Cronin CG. Imaging of bone metastasis: an update. World J Radiol 2015;7:202-11. DOI PubMed PMC
35. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol
2004;22:2942-53. DOI PubMed
36. Rieden K. Conventional imaging and computerized tomography in diagnosis of skeletal metastases. Radiologe 1995;35:15-20.
PubMed
37. Pathak AP. Magnetic resonance imaging of tumor physiology. Methods Mol Med 2006;124:279-97. DOI PubMed
38. Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: a meta-analysis comparing 18FDG PET, CT, MRI and
bone scintigraphy. Eur Radiol 2011;21:2604-17. DOI PubMed
39. Fogelman I, Cook G, Israel O, Van der Wall H. Positron emission tomography and bone metastases. Semin Nucl Med 2005;35:135-42.
DOI PubMed
40. Wu HC, Yen RF, Shen YY, Kao CH, Lin CC, Lee CC. Comparing whole body 18F-2-deoxyglucose positron emission tomography
and technetium-99m methylene diphosphate bone scan to detect bone metastases in patients with renal cell carcinomas - a preliminary
report. J Cancer Res Clin Oncol 2002;128:503-6. DOI PubMed
41. Sohaib SA, Cook G, Allen SD, Hughes M, Eisen T, Gore M. Comparison of whole-body MRI and bone scintigraphy in the detection
of bone metastases in renal cancer. Br J Radiol 2009;82:632-9. DOI PubMed
42. Coleman RE. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clin Cancer Res 2006;12:6243s-9s. DOI
PubMed
43. Roelofs AJ, Thompson K, Gordon S, Rogers MJ. Molecular mechanisms of action of bisphosphonates: current status. Clin Cancer Res
2006;12:6222s-30s. DOI PubMed
44. Elomaa I, Blomqvist C, Porkka L, et al. Treatment of skeletal disease in breast cancer: a controlled clodronate trial. Bone 1987;8 Suppl
1:S53-6. PubMed
45. Paterson AH, Powles TJ, Kanis JA, McCloskey E, Hanson J, Ashley S. Double-blind controlled trial of oral clodronate in patients with
bone metastases from breast cancer. J Clin Oncol 1993;11:59-65. DOI PubMed
46. Hortobagyi GN, Theriault RL, Porter L, et al. Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer
and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785-91. DOI PubMed
47. Theriault RL, Lipton A, Hortobagyi GN, et al. Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic
bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846-54.
DOI PubMed
48. Rosen LS, Gordon D, Kaminski M, et al. Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with
breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Cancer J 2001;7:377-87. PubMed
49. Costa L. Which bisphosphonate to treat bone metastases? Lancet Oncol 2014;15:15-6. DOI PubMed
50. Rosen LS, Gordon D, Tchekmedyian S, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with
lung cancer and other solid tumors: a phase III, double-blind, randomized trial--the Zoledronic Acid Lung Cancer and Other Solid
Tumors Study Group. J Clin Oncol 2003;21:3150-7. DOI PubMed
51. Broom RJ, Hinder V, Sharples K, et al. Everolimus and zoledronic acid in patients with renal cell carcinoma with bone metastases: a
randomized first-line phase II trial. Clin Genitourin Cancer 2015;13:50-8. DOI PubMed
52. Lipton A, Fizazi K, Stopeck AT, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a
combined analysis of 3 pivotal, randomised, phase 3 trials. Eur J Cancer 2012;48:3082-309. DOI PubMed
53. Lacey DL, Boyle WJ, Simonet WS, et al. Bench to bedside: elucidation of the OPG-RANK-RANKL pathway and the development of
denosumab. Nat Rev Drug Discov 2012;11:401-19. DOI PubMed
54. Henry DH, Costa L, Goldwasser F, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of
bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. J Clin Oncol
2011;29:1125-32. DOI PubMed
55. Motzer RJ, Hutson TE, Cella D, et al. Pazopanib versus sunitinib in metastatic renal-cell carcinoma. N Engl J Med 2013;369:722-31.
DOI PubMed
56. Costa L, Fizazi K, Saad F, et al. Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.
JCO 2013;31:5079-5079. DOI
57. Stopeck AT, Fizazi K, Body JJ, et al. Safety of long-term denosumab therapy: results from the open label extension phase of two phase
3 studies in patients with metastatic breast and prostate cancer. Support Care Cancer 2016;24:447-55. DOI PubMed PMC